Virtue Capital Management LLC Sells 5,865 Shares of Johnson & Johnson (NYSE:JNJ)

Virtue Capital Management LLC reduced its position in Johnson & Johnson (NYSE:JNJGet Rating) by 54.5% during the second quarter, HoldingsChannel reports. The firm owned 4,900 shares of the company’s stock after selling 5,865 shares during the period. Virtue Capital Management LLC’s holdings in Johnson & Johnson were worth $870,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. RE Dickinson Investment Advisors LLC lifted its position in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock valued at $28,000 after acquiring an additional 98 shares during the period. Advanced Research Investment Solutions LLC lifted its position in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock valued at $32,000 after acquiring an additional 120 shares during the period. Morton Brown Family Wealth LLC raised its holdings in Johnson & Johnson by 78.0% during the second quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after buying an additional 78 shares during the last quarter. Professional Financial Advisors LLC raised its holdings in Johnson & Johnson by 47.9% during the first quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after buying an additional 68 shares during the last quarter. Finally, Goodman Advisory Group LLC acquired a new position in Johnson & Johnson during the second quarter worth $39,000. 68.59% of the stock is owned by institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,366,753.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,410 shares of the stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $173.42, for a total transaction of $2,845,822.20. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at $12,366,753.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Hait sold 15,000 shares of the stock in a transaction dated Monday, October 24th. The stock was sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now owns 80,236 shares of the company’s stock, valued at approximately $13,764,485.80. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 118,795 shares of company stock worth $20,230,174. 0.35% of the stock is owned by company insiders.

Analyst Ratings Changes

JNJ has been the topic of several research reports. Atlantic Securities lowered their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Bank of America lowered their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Sanford C. Bernstein lowered their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Barclays initiated coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective on the stock. Finally, StockNews.com initiated coverage on shares of Johnson & Johnson in a research note on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Seven investment analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.33.

Johnson & Johnson Price Performance

JNJ opened at $176.20 on Friday. The firm has a market cap of $460.67 billion, a P/E ratio of 24.54, a PEG ratio of 3.47 and a beta of 0.57. The firm has a 50-day moving average of $167.84 and a 200 day moving average of $171.35. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to analyst estimates of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.60 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson declared that its Board of Directors has authorized a share repurchase program on Wednesday, September 14th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the company to buy up to 1.2% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 annualized dividend and a yield of 2.57%. Johnson & Johnson’s payout ratio is currently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.